Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ: IXHL )

2.733 +0.213 (+8.45%)
Streaming Delayed Price Updated: 3:21 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Marijuana Stock Movers For August 1, 2023
Via Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
Incannex Healthcare: Is Life Better On Nasdaq?
Incannex Healthcare is planning to redomicile to the US in a move designed to access deeper pools of capital and increase the company’s long-term market valuation. We interview the CEO of the... 
Via Talk Markets
Cannabis Stock Gainers And Losers From July 28, 2023
Via Benzinga
Incannex thrilled with positive pre-IND meeting for arthritis treatment
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting... 
Via TheNewswire.com
Exposures Product Safety
Incannex thrilled with positive pre-IND meeting for arthritis treatment
--News Direct-- 
Via News Direct
Exposures Product Safety
Cannabis Stock Gainers And Losers From July 26, 2023
Via Benzinga
Incannex Completes Positive Pre-IND Meeting With FDA On CBD-Based Drug For Treatment Of Rheumatoid Arthritis
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has completed a constructive pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. 
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
Incannex Submits IND Application To The FDA For Dronabinol-Based Drug For Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has successfully submitted an Investigational New Drug (‘IND’) application to the US Food and Drug Administration for IHL-42X for treatment of... 
Via Benzinga
Cannabis Stock Movers For July 19, 2023
Via Benzinga
Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical... 
Via TheNewswire.com
Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial
--News Direct-- 
Via News Direct
Fortrea To Manage Incannex's FDA IND Opening Phase 2/3 Trial Of Its Dronabinol-Based Drug For Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) has engaged Fortrea (NASDAQ: FTRE) as the contract research organisation for management of the IND opening p 
Via Benzinga
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
Incannex Receives HREC Approval For Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its... 
Via Benzinga
Incannex CEO talks plans to redomicile to US
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun the process of shifting all outstanding shares to the Nasdaq after making the decision to redomicile... 
Via TheNewswire.com
Incannex CEO talks plans to redomicile to US
Incannex CEO talks plans to redomicile to US 
Via News Direct
Incannex To Redomicile To United States, List All Shares On Nasdaq
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) intends to redomicile from Australia to the United States via proposed schemes of arrangement between Incannex and its shareholders (share scheme)... 
Via Benzinga
Psychedelic Stocks Jumped 10% Last Week
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
Incannex appoints principal investigators for pivotal IHL-42X trial
Incannex appoints principal investigators for pivotal IHL-42X trial 
Via News Direct
Exposures Product Safety
Incannex appoints principal investigators for pivotal IHL-42X trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X,... 
Via TheNewswire.com
Exposures Product Safety
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.